Parkev Tatevosian, CFA on $CLX

Channel profile →Sources cited by the channel: Barclays analyst Dan Levy, Meta management and CEO Mark Zuckerberg, Nike management2 entries

Parkev Tatevosian, CFA has discussed $CLX in 2 videos since 2026-10-02. The latest, on 2026-10-24, was bullish.

2026-10-24Bullish
“Macroeconomic Headwinds are Hitting Clorox From All Sides | CLX Stock Analysis”
AI summary · Clorox is reaffirmed as a buy: at $87 versus a $100 valuation based on slightly lowered cash-flow estimates, and 14.25x forward earnings, it looks undervalued on both forward P/E and discounted cash flow. Conviction is cut to low, as sales fell 5% and margins sit at 13.2% versus a normal 18-20%.

The fiscal year 2026 was extremely difficult for Clorox. Consumers have become more value-conscious and have begun to buy lesser-known products at cheaper prices. At the same time, Clorox's operating costs were increasing as a result of tariffs and the war in Iran.

Net sales fell by 5%, and profits declined even further. Adding to the concern, the CEO resigned for health reasons , and they are still looking for a replacement. So, does all this mean that investors should run away from Clorox, or is it a buying opportunity to seize the company when its price drops?

2026-10-02Bullish
“Clorox is Dealing With Several Years of Challenging Circumstances | CLX Stock Analysis”
AI summary · CLX is a buy for long-term investors; fair value $110 vs price $81 implies >34% upside in 12-18 months, supported by 13x forward P/E and >6% dividend yield despite margin decline.

Consumer staples companies like Clorox are facing similar headwinds. To do this, one of the methods they use is to switch from branded products such as Clorox and Procter & Gamble to store-branded products .

Such as the brands " Kroger", " Amazon Basics", and others that you see sold alongside popular products like "Clorox" and "Procter & Gamble".